Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | TSPO | P30536 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574961 | 0.90 | ALDH1A1 (0.61) | MAOBNOX1ALDH1A1ALOX5NR4A1 | |
| SCHEMBL192404 | 0.90 | ALDH1A1 (0.49) | MAOBNOX1ALDH1A1ALOX5NR4A1 | |
| SCHEMBL17890894 | 0.89 | NOX1 (0.54) | MAOBNOX1ALDH1A1ALOX5NR4A1 | |
| SCHEMBL2292934 | 0.84 | SMN1; SMN2 (0.45) | FFAR1 | |
| SCHEMBL219603 | 0.84 | SMN1; SMN2 (0.49) | ALDH1A1MEN1KMT2A | |
| SCHEMBL193278 | 0.84 | SMN1; SMN2 (0.43) | NOX1ALDH1A1ALOX5PTGS1PTGS2 | |
| SCHEMBL1350475 | 0.83 | MAOB (0.43) | MAOB | |
| SCHEMBL3104540 | 0.82 | NOX1 (0.50) | MAOBNOX1ALDH1A1ALOX5NR4A1 | |
| SCHEMBL11649618 | 0.82 | PTPN1 (0.42) | MEN1MAPTKMT2A | |
| SCHEMBL3813554 | 0.82 | NR1H2 (0.41) | ALDH1A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877366-B1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2012-01-04 | — | — | EP | disclosed |
| EP-1893634-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-8048881-B2 | Uding 4-aminocarbonyl-pyrimidine; vascular disorders; cardiovascular disorders; thrombosis; brain disorders; vision defects | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7973181-B2 | Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| EP-1362855-B1 | BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
| US-7045515-B2 | β-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-16 | — | — | US | disclosed |
| US-20040063929-A1 | Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1362855-A1 | BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | MAOB 375/4885NOX1 132/4885ALDH1A1 348/4885 |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | MAOB 1830/4885NOX1 1787/4885ALDH1A1 1522/4885 |
| US-20040063929-A1 | Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | HMGCR, NCEH1, CETP | MAOB 2760/4885NOX1 1059/4885ALDH1A1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.